Mohammed Asmal

Vice Presdient and Head of Clinical Research & Development
bluebird bio
Mohammed Asmal
Mohammed Asmal, MD-PhD, leads the Clinical Research and Development team of physicians and pharmacists in the Severe Genetic Diseases Franchise at bluebird bio, responsible for overseeing the design, execution and interpretation of clinical trials of lentiviral-based gene therapy in transfusion-dependent thalassemia, sickle cell disease and cerebral adrenoleukodystrophy. Prior to bluebird, Mohammed led trials of small molecule therapeutics for cancer, hepatitis C and influenza at Vertex Pharmaceuticals. Mohammed obtained his MD and PhD in molecular biology at Columbia College of Physicians and Surgeons, and completed a residency in Internal Medicine and fellowship in Infectious Diseases at the Brigham and Women’s Hospital, followed by post-doctoral research in nonhuman primate models of HIV infection and vaccination at Harvard Medical School.


No data was found

Cell Series 2019
Post-Event Report

Statistics, feedback, photos and more from last year's event